Patents Assigned to 89Bio, Inc.
  • METHODS OF TREATMENT OF NASH USING MUTANT FGF-21 PEPTIDE CONJUGATES
    Publication number: 20260201005
    Abstract: Therapeutic regimens and uses of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates in the treatment of nonalcoholic steatohepatitis are provided.
    Type: Application
    Filed: August 24, 2023
    Publication date: July 16, 2026
    Applicant: 89Bio, Inc.
    Inventors: Harry H. Mansbach, Maya Margalit
  • LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES
    Publication number: 20250381246
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Application
    Filed: June 3, 2025
    Publication date: December 18, 2025
    Applicant: 89Bio, Inc.
    Inventors: Boris Schwartsburd, Shaji Joseph
  • Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates
    Patent number: 12350314
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Grant
    Filed: November 8, 2023
    Date of Patent: July 8, 2025
    Assignee: 89bio, Inc.
    Inventors: Boris Schwartsburd, Shaji Joseph
  • COMPOSITIONS AND METHODS OF TREATMENT FOR SEVERE HYPERTRIGLYCERIDEMIA
    Publication number: 20250170249
    Abstract: Compositions, methods and therapeutic regimens of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.
    Type: Application
    Filed: June 4, 2024
    Publication date: May 29, 2025
    Applicant: 89bio, Inc.
    Inventors: Hank Mansbach, Leo Tseng
  • CHEMICAL SYNTHESIS OF CYTIDINE-5'-MONOPHOSPHO-N-GLYCYL-SIALIC ACID
    Publication number: 20240327447
    Abstract: Aspects of the present disclosure provide methods for the chemical synthesis of cytidine-5?-monophospho-N-glycyl-sialic acid (GSC).
    Type: Application
    Filed: June 12, 2024
    Publication date: October 3, 2024
    Applicant: 89bio, Inc.
    Inventors: Shaji Joseph, Arthur Bodenmüller
  • LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES
    Publication number: 20240307492
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Application
    Filed: November 8, 2023
    Publication date: September 19, 2024
    Applicant: 89bio, Inc.
    Inventors: Boris Schwartsburd, Shaji Joseph
  • Compositions and methods of treatment for severe hypertriglyceridemia
    Patent number: 12036284
    Abstract: Compositions, methods and therapeutic regimens of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.
    Type: Grant
    Filed: June 23, 2023
    Date of Patent: July 16, 2024
    Assignee: 89bio, Inc.
    Inventors: Hank Mansbach, Leo Tseng
  • COMPOSITIONS AND METHODS OF TREATMENT FOR SEVERE HYPERTRIGLYCERIDEMIA
    Publication number: 20230414768
    Abstract: Compositions, methods and therapeutic regimens of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.
    Type: Application
    Filed: June 23, 2023
    Publication date: December 28, 2023
    Applicant: 89bio, Inc.
    Inventors: Hank Mansbach, Leo Tseng
  • Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates
    Patent number: 11850275
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Grant
    Filed: February 6, 2023
    Date of Patent: December 26, 2023
    Assignee: 89bio, Inc.
    Inventors: Boris Schwartsburd, Shaji Joseph
  • LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES
    Publication number: 20230338471
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Application
    Filed: February 6, 2023
    Publication date: October 26, 2023
    Applicant: 89BIO, INC.
    Inventors: Boris SCHWARTSBURD, Shaji JOSEPH
  • Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates
    Patent number: 11596669
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: March 7, 2023
    Assignee: 89BIO, INC.
    Inventors: Boris Schwartsburd, Shaji Joseph
  • LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES
    Publication number: 20220296678
    Abstract: The present disclosure relates to liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate and prefilled syringe or autoinjector comprising liquid pharmaceutical compositions comprising mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate.
    Type: Application
    Filed: March 10, 2022
    Publication date: September 22, 2022
    Applicant: 89Bio, Inc.
    Inventors: Boris Schwartsburd, Shaji Joseph